OATP-A inhibitors represent a chemically defined class of compounds known for their distinct capability to modulate the function of organic anion transporting polypeptide A (OATP-A) proteins. These transporters are integral constituents of cell membranes, prominently expressed in diverse human tissues, including the liver, kidneys, and intestines. OATP-A proteins play a vital role in facilitating the transmembrane transport of a broad spectrum of molecules, encompassing endogenous compounds like bilirubin, hormones, and metabolites, as well as exogenous substances such as environmental toxins. The precise mechanism of OATP-A inhibitors involves their interaction with the transmembrane domains of the transporter proteins. This interaction can occur through reversible binding to specific sites on the OATP-A protein structure. In some cases, these inhibitors compete directly with the substrates for the binding sites within the transporter's translocation channel, thereby hindering the uptake of substrates.
Alternatively, OATP-A inhibitors can induce conformational alterations in the transporter's structure, leading to a reduced affinity for substrates or impeded translocation across the lipid bilayer. The design and exploration of OATP-A inhibitors hold significant importance in unraveling the complexities of cellular transport processes. Investigating these inhibitors allows researchers to gain insights into the molecular mechanisms underpinning substrate recognition, binding, and translocation by OATP-A proteins. Moreover, these inhibitors have the potential to serve as invaluable tools in elucidating the physiological and pharmacological roles of OATP-A transporters in various tissues and organs. While the focus of OATP-A inhibitors lies primarily within research contexts, their study has the potential to contribute to a broader understanding of cellular transport phenomena and receptor-ligand interactions. By elucidating the mechanisms of inhibition and interaction with OATP-A transporters, researchers can expand their knowledge of how molecules traverse cellular membranes, leading to advancements in fields such as drug delivery, pharmacology, and cellular biology.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gemfibrozil | 25812-30-0 | sc-204764 sc-204764A | 5 g 25 g | $66.00 $267.00 | 2 | |
A agent in research used to lower cholesterol and triglycerides. It's known to inhibit OATP1B1. | ||||||
Atazanavir | 198904-31-3 | sc-207305 | 5 mg | $292.00 | 7 | |
An antiretroviral drug that can inhibit OATP1B1. | ||||||
12β-Hydroxydigitoxin | 20830-75-5 | sc-213604 sc-213604A | 1 g 5 g | $143.00 $694.00 | ||
A agent in research used for heart conditions. It's a substrate and inhibitor of various OATP transporters. | ||||||
Nelfinavir | 159989-64-7 | sc-507314 | 10 mg | $168.00 | ||
Pravastatin, Sodium Salt | 81131-70-6 | sc-203218 sc-203218A sc-203218B | 25 mg 100 mg 1 g | $69.00 $162.00 $787.00 | 2 | |
A statin agent in research used to lower cholesterol. It's a substrate and inhibitor of OATP1B1. | ||||||
Bosentan | 147536-97-8 | sc-210957 | 10 mg | $195.00 | 3 | |
Used for pulmonary arterial hypertension. It inhibits OATP1B1 and OATP1B3. | ||||||
Cimetidine | 51481-61-9 | sc-202996 sc-202996A | 5 g 10 g | $62.00 $86.00 | 1 | |
An H2 receptor antagonist used to reduce stomach acid production. It can inhibit OATP1A2 and OATP1B1. | ||||||
Quinidine | 56-54-2 | sc-212614 | 10 g | $104.00 | 3 | |
Used for certain heart rhythm problems. It can inhibit OATP1B1. | ||||||
Rosuvastatin | 287714-41-4 | sc-481834 | 10 mg | $145.00 | 8 | |
Another statin used to lower cholesterol. It's a substrate and inhibitor of OATP1B1. | ||||||